Your browser doesn't support javascript.
loading
Tanshinone IIA promotes apoptosis by downregulating BCL2 and upregulating TP53 in triple-negative breast cancer.
Liu, Jinfeng; Zhang, Chang; Liu, Shuang; Wang, Xiaokang; Wu, Xiongzhi; Hao, Jian.
Afiliação
  • Liu J; Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for China, Tianjin, 300060, China.
  • Zhang C; Department of Traditional Chinese Medicine, General Hospital of Pingmei Shenma Group, Pingdingshan, 467000, China.
  • Liu S; Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for China, Tianjin, 300060, China.
  • Wang X; Department of General Surgery, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200086, China.
  • Wu X; Oncology Research Center of Integrated Traditional Chinese and Western Medicine, Tianjin Medical University Nankai Hospital, Nankai District, Changjiang Road, Tianjin, 300102, China. wuxiongzhi@163.com.
  • Hao J; Department of Rheumatism and Immunology, Tianjin Medical University General Hospital, An-Shan Road, Heping District, Tianjin, 300052, China. bingxin@tmu.edu.cn.
Naunyn Schmiedebergs Arch Pharmacol ; 396(2): 365-374, 2023 02.
Article em En | MEDLINE | ID: mdl-36374307
Tanshinone IIA (Tan IIA) was mainly used for cardiovascular disease treatment. Recent studies have demonstrated the role of Tan IIA for tumor treatment, but its mechanism remains unclear. At the first, the inhibitory effect of Tan IIA on 4T1 breast cancer cells was determined by CCK8 and colony formation assay. Then, a 4T1 BALB/c model of breast cancer was established to evaluate the anti-cancer effect of Tan IIA in vivo. Flow cytometry analysis and the TUNEL test were used to detect cell apoptosis in vitro and in vivo, respectively. The related targets and mechanisms of Tan IIA were predicted through network-based systems biology. At last, molecular docking and the molecular biological techniques were used to evaluate the predicted targets. Tan IIA displayed encouraging inhibitory influences on 4T1 cells after incubation for 24 h and showed a half-maximal inhibitory concentration (IC50) of 49.78 µM after 48-h incubation. After 23 days of treatment, the relative tumor volumes in the Tan IIA group were 65.53% inhibited compared with the control group. Furthermore, Tan IIA induced 4T1 cell apoptosis both in vivo and in vitro. The possible targets of Tan IIA for TNBC treatment were predicted with network-based systems biology, and results showed that TP53, NF-κB, AKT, MYC, and BCL-2 were the hub targets. The mechanism against breast cancer may be based on the P53 signaling pathway, the PI3K/Akt pathway, the MAPK signaling pathway, and the mTOR signaling pathways. Molecular docking analysis reveals that Tan IIA has a high affinity for p53, Bcl-2, and NF-κB1; the binding energies were - 6.92, - 6.07, and - 6.28 kcal/mol, respectively. The predicted proteins were further validated using Western blotting. Increased expression of phosphorylated p53 and p53 and decreased expression of Bcl-2 were found in Tan IIA-treated 4T1 cells. Tan IIA is potentially effective for the treatment of 4T1 breast cancer, and the molecular mechanism may be through enhancing the activity of p53 and decreasing Bcl-2 to suppress proliferation and promote apoptosis.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 6_ODS3_enfermedades_notrasmisibles Base de dados: MEDLINE Assunto principal: Neoplasias de Mama Triplo Negativas / Antineoplásicos Fitogênicos Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: Naunyn Schmiedebergs Arch Pharmacol Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 6_ODS3_enfermedades_notrasmisibles Base de dados: MEDLINE Assunto principal: Neoplasias de Mama Triplo Negativas / Antineoplásicos Fitogênicos Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: Naunyn Schmiedebergs Arch Pharmacol Ano de publicação: 2023 Tipo de documento: Article